Sotera Health Company (SHC) 10-Year Financial Performance & Capital Metrics

SHC • • Industrial / General

HealthcareDiagnostics & ResearchContract Research & Clinical Trial ServicesResearch Support Services

AboutSotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.Show more

Revenue $1.1B +4.9%
EBITDA $461M +6.1%
Net Income $44M -13.6%
EPS (Diluted) 0.16 -11.1%
Gross Margin 54.73% -0.5%
EBITDA Margin 41.92% +1.2%
Operating Margin 27.05% +2.6%
Net Margin 4.03% -17.6%
ROE 10.46% -19.1%
ROIC 9.01% -3.1%
Debt/Equity 5.81 +10.7%
Interest Coverage 1.81 -6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓High quality earnings: Operating CF exceeds net income
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 5.8x
✗Expensive at 13.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y7.17%

3Y5.71%

TTM2.67%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-27.58%

TTM-21.67%

EPS CAGR

10Y-

5Y-

3Y-26.92%

TTM-22.9%

ROCE

10Y Avg8.47%

5Y Avg9.76%

3Y Avg10.3%

Latest10.3%

Peer Comparison

Research Support Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRLCharles River Laboratories International, Inc.	11B	223.47	1117.35	-1.92%	-2.07%	-2.42%	4.56%	0.78
SHCSotera Health Company	5.5B	19.35	120.94	4.88%	4.82%	10.07%	0.82%	5.81
ISPCiSpecimen Inc.	4.22M	0.42	-0.02	-6.42%	-343.99%	-375.34%		0.09
NOTVInotiv, Inc.	19.59M	0.57	-0.27	4.54%	-13.38%	-50.45%		3.01
ACRSAclaris Therapeutics, Inc.	289.28M	2.67	-1.56	-40.09%	-9%	-117.97%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	746.15M	778.33M	818.16M	931.48M	1B	1.05B	1.1B
Revenue Growth %	-	0.04%	0.05%	0.14%	0.08%	0.05%	0.05%
Cost of Goods Sold+	388.9M	382.9M	374.59M	412.81M	446.68M	472.13M	498.15M
COGS % of Revenue	0.52%	0.49%	0.46%	0.44%	0.45%	0.45%	0.45%
Gross Profit+	357.25M	395.43M	443.57M	518.67M	557M	577.16M	602.29M
Gross Margin %	0.48%	0.51%	0.54%	0.56%	0.55%	0.55%	0.55%
Gross Profit Growth %	-	0.11%	0.12%	0.17%	0.07%	0.04%	0.04%
Operating Expenses+	191.34M	211.83M	237.55M	261.94M	308.65M	300.47M	304.67M
OpEx % of Revenue	0.26%	0.27%	0.29%	0.28%	0.31%	0.29%	0.28%
Selling, General & Admin	133.36M	147.48M	178.53M	198.16M	245.71M	236.67M	242.63M
SG&A % of Revenue	0.18%	0.19%	0.22%	0.21%	0.24%	0.23%	0.22%
Research & Development	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	143.04M	64.35M	59.03M	63.78M	62.94M	63.8M	62.04M
Operating Income+	80.85M	183.6M	206.02M	256.73M	248.35M	276.69M	297.63M
Operating Margin %	0.11%	0.24%	0.25%	0.28%	0.25%	0.26%	0.27%
Operating Income Growth %	-	1.27%	0.12%	0.25%	-0.03%	0.11%	0.08%
EBITDA+	227.66M	330.32M	349.58M	407.63M	393.9M	434.62M	461.26M
EBITDA Margin %	0.31%	0.42%	0.43%	0.44%	0.39%	0.41%	0.42%
EBITDA Growth %	-	0.45%	0.06%	0.17%	-0.03%	0.1%	0.06%
D&A (Non-Cash Add-back)	146.82M	146.72M	143.56M	150.9M	145.55M	157.93M	163.64M
EBIT	167.55M	156.81M	176.4M	249.91M	-162.97M	248.91M	278.56M
Net Interest Income+	-143.33M	-157.73M	-215.26M	-74.19M	-80.14M	-142.88M	-164.69M
Interest Income	0	0	0	0	0	0	0
Interest Expense	143.33M	157.73M	215.26M	74.19M	80.14M	142.88M	164.69M
Other Income/Expense	-56.63M	-184.51M	-244.88M	-81.02M	-491.46M	-170.66M	-183.75M
Pretax Income+	24.22M	-916K	-38.86M	175.72M	-243.11M	106.03M	113.87M
Pretax Margin %	0.03%	-0%	-0.05%	0.19%	-0.24%	0.1%	0.1%
Income Tax+	30.1M	19.51M	-1.37M	58.59M	-9.54M	54.65M	69.48M
Effective Tax Rate %	-0.24%	22.76%	0.99%	0.67%	0.96%	0.48%	0.39%
Net Income+	-5.87M	-20.85M	-38.62M	116.88M	-233.57M	51.38M	44.4M
Net Margin %	-0.01%	-0.03%	-0.05%	0.13%	-0.23%	0.05%	0.04%
Net Income Growth %	-	-2.55%	-0.85%	4.03%	-3%	1.22%	-0.14%
Net Income (Continuing)	-5.88M	-20.43M	-37.49M	117.12M	-233.57M	51.38M	44.4M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	1.13M	1.44M	2.27M	0	0	0	0
EPS (Diluted)+	-0.02	-0.07	-0.14	0.41	-0.83	0.18	0.16
EPS Growth %	-	-2.02%	-0.95%	3.93%	-3.02%	1.22%	-0.11%
EPS (Basic)	-0.02	-0.07	-0.14	0.41	-0.83	0.18	0.16
Diluted Shares Outstanding	246.15M	284.42M	283.25M	279.38M	280.1M	283.22M	284.91M
Basic Shares Outstanding	246.15M	284.42M	283.25M	279.23M	280.1M	281.01M	282.78M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	312.86M	252.35M	315.01M	345.96M	645.01M	557.24M	526.04M
Cash & Short-Term Investments	96.27M	62.86M	102.45M	106.92M	395.21M	296.41M	277.24M
Cash Only	96.27M	62.86M	102.45M	106.92M	395.21M	296.41M	277.24M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	141.61M	111.58M	131.02M	134.05M	155.72M	175.52M	165.81M
Days Sales Outstanding	69.27	52.33	58.45	52.53	56.63	61.06	55
Inventory	37.6M	37.4M	34.09M	54.29M	37.15M	48.32M	49.16M
Days Inventory Outstanding	35.29	35.65	33.22	48	30.35	37.35	36.02
Other Current Assets	12.15M	10.84M	10.74M	11.19M	16.56M	20.91M	16.58M
Total Non-Current Assets+	2.4B	2.33B	2.45B	2.44B	2.47B	2.57B	2.55B
Property, Plant & Equipment	586.44M	581.95M	655.78M	690.74M	801.01M	970.95M	1.06B
Fixed Asset Turnover	1.27x	1.34x	1.25x	1.35x	1.25x	1.08x	1.03x
Goodwill	1.02B	1.04B	1.12B	1.12B	1.1B	1.11B	1.08B
Intangible Assets	766.05M	696.01M	643.37M	598.84M	491.26M	416.32M	317.65M
Long-Term Investments	0	0	13.46M	9.4M	0	0	0
Other Non-Current Assets	4.15M	12.24M	9.3M	18.34M	74.55M	69.72M	79.58M
Total Assets+	2.71B	2.58B	2.76B	2.79B	3.12B	3.13B	3.07B
Asset Turnover	0.28x	0.30x	0.30x	0.33x	0.32x	0.34x	0.36x
Asset Growth %	-	-0.05%	0.07%	0.01%	0.12%	0%	-0.02%
Total Current Liabilities+	143.37M	123.99M	140.6M	161.16M	791.57M	230.65M	191M
Accounts Payable	46.35M	42M	52.4M	72.87M	74.14M	71.04M	55.1M
Days Payables Outstanding	43.51	40.04	51.06	64.43	60.58	54.92	40.37
Short-Term Debt	15.34M	16.33M	0	0	197.12M	4.8M	14.8M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	50.65M	37.34M	38.8M	37.21M	43.12M	36.93M	41.12M
Current Ratio	2.18x	2.04x	2.24x	2.15x	0.81x	2.42x	2.75x
Quick Ratio	1.92x	1.73x	2.00x	1.81x	0.77x	2.21x	2.50x
Cash Conversion Cycle	61.06	47.93	40.61	36.1	26.4	43.49	50.64
Total Non-Current Liabilities+	2.52B	3.1B	2.17B	2.04B	1.98B	2.46B	2.48B
Long-Term Debt	2.19B	2.8B	1.82B	1.74B	1.75B	2.22B	2.21B
Capital Lease Obligations	31.54M	29.88M	73.88M	73.89M	78.53M	83.88M	119.75M
Deferred Tax Liabilities	171.48M	137.24M	121.82M	134.5M	68.02M	64.45M	69.5M
Other Non-Current Liabilities	106.18M	108.45M	124.37M	69.57M	63.33M	65.26M	61.6M
Total Liabilities	2.66B	3.22B	2.31B	2.2B	2.77B	2.69B	2.67B
Total Debt+	2.24B	2.85B	1.91B	1.83B	2.03B	2.33B	2.35B
Net Debt	2.14B	2.79B	1.81B	1.72B	1.64B	2.03B	2.07B
Debt / Equity	49.19x	-	4.20x	3.12x	5.80x	5.24x	5.81x
Debt / EBITDA	9.83x	8.62x	5.46x	4.48x	5.16x	5.35x	5.10x
Net Debt / EBITDA	9.41x	8.43x	5.17x	4.22x	4.16x	4.67x	4.50x
Interest Coverage	0.56x	1.16x	0.96x	3.46x	3.10x	1.94x	1.81x
Total Equity+	45.49M	-641.13M	454.57M	586.1M	350.24M	443.73M	404.91M
Equity Growth %	-	-15.09%	1.71%	0.29%	-0.4%	0.27%	-0.09%
Book Value per Share	0.18	-2.25	1.60	2.10	1.25	1.57	1.42
Total Shareholders' Equity	44.36M	-642.57M	452.3M	586.1M	350.24M	443.73M	404.91M
Common Stock	2.32M	2.32M	2.86M	2.86M	2.86M	2.86M	2.86M
Retained Earnings	-10.42M	-550.51M	-589.13M	-472.25M	-705.82M	-654.44M	-610.04M
Treasury Stock	0	0	-34M	-33.55M	-29.77M	-27.18M	-23.43M
Accumulated OCI	-109.96M	-94.39M	-93.84M	-83.57M	-106.65M	-92.68M	-208.25M
Minority Interest	1.13M	1.44M	2.27M	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	119.56M	149.04M	120.58M	281.55M	277.96M	-147.73M	224.16M
Operating CF Margin %	0.16%	0.19%	0.15%	0.3%	0.28%	-0.14%	0.2%
Operating CF Growth %	-	0.25%	-0.19%	1.33%	-0.01%	-1.53%	2.52%
Net Income	-5.88M	-20.43M	-37.49M	117.12M	-233.57M	51.38M	44.4M
Depreciation & Amortization	146.82M	146.72M	143.56M	150.9M	145.55M	160.34M	163.64M
Stock-Based Compensation	6.94M	6.88M	10.99M	13.87M	21.21M	32.24M	36.78M
Deferred Taxes	-45.32M	-18.99M	-23.36M	-3.72M	-73.96M	3.45M	9.43M
Other Non-Cash Items	12.96M	43.21M	38.68M	15.96M	9.49M	8.15M	12.55M
Working Capital Changes	4.04M	-8.35M	-11.79M	-12.59M	409.23M	-403.29M	-42.63M
Change in Receivables	-2.91M	11.76M	1.94M	-15.51M	-12.55M	-21.72M	2.22M
Change in Inventory	-7.04M	-282K	3.78M	-20.25M	14.44M	-9.97M	-4.75M
Change in Payables	15.13M	-8.97M	-6.02M	19.76M	1.11M	-5.33M	-6.64M
Cash from Investing+	96.64M	-57.26M	-158.69M	-159.83M	-181.9M	-214.91M	-179M
Capital Expenditures	-72.61M	-57.26M	-53.51M	-102.16M	-182.38M	-214.97M	-179.07M
CapEx % of Revenue	0.1%	0.07%	0.07%	0.11%	0.18%	0.2%	0.16%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	6.43M	0	0	-701K	32K	69K	74K
Cash from Financing+	-191.86M	-126.03M	73.43M	-117.29M	197.76M	265.96M	-50.56M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-175.84M	-691.17M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-1.38M	-18.38M	-21.2M	-15.85M	-1.85M	-27.45M	-34.38M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	46.95M	91.78M	67.08M	179.38M	95.58M	-362.71M	45.09M
FCF Margin %	0.06%	0.12%	0.08%	0.19%	0.1%	-0.35%	0.04%
FCF Growth %	-	0.95%	-0.27%	1.67%	-0.47%	-4.79%	1.12%
FCF per Share	0.19	0.32	0.24	0.64	0.34	-1.28	0.16
FCF Conversion (FCF/Net Income)	-20.37x	-7.15x	-3.12x	2.41x	-1.19x	-2.88x	5.05x
Interest Paid	138.85M	151M	211.28M	58.77M	75.85M	173.84M	179.92M
Taxes Paid	68.61M	44.61M	23.99M	52.01M	75.5M	50.21M	65.83M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-12.9%	-	-8.5%	22.46%	-49.89%	12.94%	10.46%
Return on Invested Capital (ROIC)	2.77%	6.36%	7.01%	8.43%	8.68%	9.3%	9.01%
Gross Margin	47.88%	50.81%	54.22%	55.68%	55.5%	55%	54.73%
Net Margin	-0.79%	-2.68%	-4.72%	12.55%	-23.27%	4.9%	4.03%
Debt / Equity	49.19x	-	4.20x	3.12x	5.80x	5.24x	5.81x
Interest Coverage	0.56x	1.16x	0.96x	3.46x	3.10x	1.94x	1.81x
FCF Conversion	-20.37x	-7.15x	-3.12x	2.41x	-1.19x	-2.88x	5.05x
Revenue Growth	-	4.31%	5.12%	13.85%	7.75%	4.54%	4.88%

Revenue by Segment

	2021	2022	2023	2024
Service	805.5M	864.83M	905.6M	941.82M
Service Growth	-	7.37%	4.71%	4.00%
Product	125.98M	138.86M	143.69M	158.62M
Product Growth	-	10.23%	3.48%	10.39%

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	527.91M	579.02M	590.97M	616.68M
UNITED STATES Growth	-	9.68%	2.06%	4.35%
CANADA	177.88M	188.74M	192.05M	208.89M
CANADA Growth	-	6.11%	1.75%	8.77%
Europe	161.81M	166.03M	187.54M	196.01M
Europe Growth	-	2.60%	12.96%	4.52%
Other Geographical Areas	63.89M	69.9M	78.73M	78.86M
Other Geographical Areas Growth	-	9.42%	12.63%	0.17%

Frequently Asked Questions

Valuation & Price

Sotera Health Company (SHC) has a price-to-earnings (P/E) ratio of 120.9x. This suggests investors expect higher future growth.

Growth & Financials

Sotera Health Company (SHC) reported $1.15B in revenue for fiscal year 2024. This represents a 54% increase from $746.1M in 2018.

Sotera Health Company (SHC) grew revenue by 4.9% over the past year. Growth has been modest.

Yes, Sotera Health Company (SHC) is profitable, generating $55.4M in net income for fiscal year 2024 (4.0% net margin).

Dividend & Returns

Sotera Health Company (SHC) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.

Sotera Health Company (SHC) generated $85.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Sotera Health Company (SHC) 10-Year Financial Performance & Capital Metrics

SHC • • Industrial / General

HealthcareDiagnostics & ResearchContract Research & Clinical Trial ServicesResearch Support Services

Revenue $1.1B +4.9%
EBITDA $461M +6.1%
Net Income $44M -13.6%
EPS (Diluted) 0.16 -11.1%
Gross Margin 54.73% -0.5%
EBITDA Margin 41.92% +1.2%
Operating Margin 27.05% +2.6%
Net Margin 4.03% -17.6%
ROE 10.46% -19.1%
ROIC 9.01% -3.1%
Debt/Equity 5.81 +10.7%
Interest Coverage 1.81 -6.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 82 (top 18%)
✓High quality earnings: Operating CF exceeds net income
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 5.8x
✗Expensive at 13.6x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y7.17%

3Y5.71%

TTM2.67%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-27.58%

TTM-21.67%

EPS CAGR

10Y-

5Y-

3Y-26.92%

TTM-22.9%

ROCE

10Y Avg8.47%

5Y Avg9.76%

3Y Avg10.3%

Latest10.3%

Peer Comparison

Research Support Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRLCharles River Laboratories International, Inc.	11B	223.47	1117.35	-1.92%	-2.07%	-2.42%	4.56%	0.78
SHCSotera Health Company	5.5B	19.35	120.94	4.88%	4.82%	10.07%	0.82%	5.81
ISPCiSpecimen Inc.	4.22M	0.42	-0.02	-6.42%	-343.99%	-375.34%		0.09
NOTVInotiv, Inc.	19.59M	0.57	-0.27	4.54%	-13.38%	-50.45%		3.01
ACRSAclaris Therapeutics, Inc.	289.28M	2.67	-1.56	-40.09%	-9%	-117.97%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	746.15M	778.33M	818.16M	931.48M	1B	1.05B	1.1B
Revenue Growth %	-	0.04%	0.05%	0.14%	0.08%	0.05%	0.05%
Cost of Goods Sold+	388.9M	382.9M	374.59M	412.81M	446.68M	472.13M	498.15M
COGS % of Revenue	0.52%	0.49%	0.46%	0.44%	0.45%	0.45%	0.45%
Gross Profit+	357.25M	395.43M	443.57M	518.67M	557M	577.16M	602.29M
Gross Margin %	0.48%	0.51%	0.54%	0.56%	0.55%	0.55%	0.55%
Gross Profit Growth %	-	0.11%	0.12%	0.17%	0.07%	0.04%	0.04%
Operating Expenses+	191.34M	211.83M	237.55M	261.94M	308.65M	300.47M	304.67M
OpEx % of Revenue	0.26%	0.27%	0.29%	0.28%	0.31%	0.29%	0.28%
Selling, General & Admin	133.36M	147.48M	178.53M	198.16M	245.71M	236.67M	242.63M
SG&A % of Revenue	0.18%	0.19%	0.22%	0.21%	0.24%	0.23%	0.22%
Research & Development	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	143.04M	64.35M	59.03M	63.78M	62.94M	63.8M	62.04M
Operating Income+	80.85M	183.6M	206.02M	256.73M	248.35M	276.69M	297.63M
Operating Margin %	0.11%	0.24%	0.25%	0.28%	0.25%	0.26%	0.27%
Operating Income Growth %	-	1.27%	0.12%	0.25%	-0.03%	0.11%	0.08%
EBITDA+	227.66M	330.32M	349.58M	407.63M	393.9M	434.62M	461.26M
EBITDA Margin %	0.31%	0.42%	0.43%	0.44%	0.39%	0.41%	0.42%
EBITDA Growth %	-	0.45%	0.06%	0.17%	-0.03%	0.1%	0.06%
D&A (Non-Cash Add-back)	146.82M	146.72M	143.56M	150.9M	145.55M	157.93M	163.64M
EBIT	167.55M	156.81M	176.4M	249.91M	-162.97M	248.91M	278.56M
Net Interest Income+	-143.33M	-157.73M	-215.26M	-74.19M	-80.14M	-142.88M	-164.69M
Interest Income	0	0	0	0	0	0	0
Interest Expense	143.33M	157.73M	215.26M	74.19M	80.14M	142.88M	164.69M
Other Income/Expense	-56.63M	-184.51M	-244.88M	-81.02M	-491.46M	-170.66M	-183.75M
Pretax Income+	24.22M	-916K	-38.86M	175.72M	-243.11M	106.03M	113.87M
Pretax Margin %	0.03%	-0%	-0.05%	0.19%	-0.24%	0.1%	0.1%
Income Tax+	30.1M	19.51M	-1.37M	58.59M	-9.54M	54.65M	69.48M
Effective Tax Rate %	-0.24%	22.76%	0.99%	0.67%	0.96%	0.48%	0.39%
Net Income+	-5.87M	-20.85M	-38.62M	116.88M	-233.57M	51.38M	44.4M
Net Margin %	-0.01%	-0.03%	-0.05%	0.13%	-0.23%	0.05%	0.04%
Net Income Growth %	-	-2.55%	-0.85%	4.03%	-3%	1.22%	-0.14%
Net Income (Continuing)	-5.88M	-20.43M	-37.49M	117.12M	-233.57M	51.38M	44.4M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	1.13M	1.44M	2.27M	0	0	0	0
EPS (Diluted)+	-0.02	-0.07	-0.14	0.41	-0.83	0.18	0.16
EPS Growth %	-	-2.02%	-0.95%	3.93%	-3.02%	1.22%	-0.11%
EPS (Basic)	-0.02	-0.07	-0.14	0.41	-0.83	0.18	0.16
Diluted Shares Outstanding	246.15M	284.42M	283.25M	279.38M	280.1M	283.22M	284.91M
Basic Shares Outstanding	246.15M	284.42M	283.25M	279.23M	280.1M	281.01M	282.78M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	312.86M	252.35M	315.01M	345.96M	645.01M	557.24M	526.04M
Cash & Short-Term Investments	96.27M	62.86M	102.45M	106.92M	395.21M	296.41M	277.24M
Cash Only	96.27M	62.86M	102.45M	106.92M	395.21M	296.41M	277.24M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	141.61M	111.58M	131.02M	134.05M	155.72M	175.52M	165.81M
Days Sales Outstanding	69.27	52.33	58.45	52.53	56.63	61.06	55
Inventory	37.6M	37.4M	34.09M	54.29M	37.15M	48.32M	49.16M
Days Inventory Outstanding	35.29	35.65	33.22	48	30.35	37.35	36.02
Other Current Assets	12.15M	10.84M	10.74M	11.19M	16.56M	20.91M	16.58M
Total Non-Current Assets+	2.4B	2.33B	2.45B	2.44B	2.47B	2.57B	2.55B
Property, Plant & Equipment	586.44M	581.95M	655.78M	690.74M	801.01M	970.95M	1.06B
Fixed Asset Turnover	1.27x	1.34x	1.25x	1.35x	1.25x	1.08x	1.03x
Goodwill	1.02B	1.04B	1.12B	1.12B	1.1B	1.11B	1.08B
Intangible Assets	766.05M	696.01M	643.37M	598.84M	491.26M	416.32M	317.65M
Long-Term Investments	0	0	13.46M	9.4M	0	0	0
Other Non-Current Assets	4.15M	12.24M	9.3M	18.34M	74.55M	69.72M	79.58M
Total Assets+	2.71B	2.58B	2.76B	2.79B	3.12B	3.13B	3.07B
Asset Turnover	0.28x	0.30x	0.30x	0.33x	0.32x	0.34x	0.36x
Asset Growth %	-	-0.05%	0.07%	0.01%	0.12%	0%	-0.02%
Total Current Liabilities+	143.37M	123.99M	140.6M	161.16M	791.57M	230.65M	191M
Accounts Payable	46.35M	42M	52.4M	72.87M	74.14M	71.04M	55.1M
Days Payables Outstanding	43.51	40.04	51.06	64.43	60.58	54.92	40.37
Short-Term Debt	15.34M	16.33M	0	0	197.12M	4.8M	14.8M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	50.65M	37.34M	38.8M	37.21M	43.12M	36.93M	41.12M
Current Ratio	2.18x	2.04x	2.24x	2.15x	0.81x	2.42x	2.75x
Quick Ratio	1.92x	1.73x	2.00x	1.81x	0.77x	2.21x	2.50x
Cash Conversion Cycle	61.06	47.93	40.61	36.1	26.4	43.49	50.64
Total Non-Current Liabilities+	2.52B	3.1B	2.17B	2.04B	1.98B	2.46B	2.48B
Long-Term Debt	2.19B	2.8B	1.82B	1.74B	1.75B	2.22B	2.21B
Capital Lease Obligations	31.54M	29.88M	73.88M	73.89M	78.53M	83.88M	119.75M
Deferred Tax Liabilities	171.48M	137.24M	121.82M	134.5M	68.02M	64.45M	69.5M
Other Non-Current Liabilities	106.18M	108.45M	124.37M	69.57M	63.33M	65.26M	61.6M
Total Liabilities	2.66B	3.22B	2.31B	2.2B	2.77B	2.69B	2.67B
Total Debt+	2.24B	2.85B	1.91B	1.83B	2.03B	2.33B	2.35B
Net Debt	2.14B	2.79B	1.81B	1.72B	1.64B	2.03B	2.07B
Debt / Equity	49.19x	-	4.20x	3.12x	5.80x	5.24x	5.81x
Debt / EBITDA	9.83x	8.62x	5.46x	4.48x	5.16x	5.35x	5.10x
Net Debt / EBITDA	9.41x	8.43x	5.17x	4.22x	4.16x	4.67x	4.50x
Interest Coverage	0.56x	1.16x	0.96x	3.46x	3.10x	1.94x	1.81x
Total Equity+	45.49M	-641.13M	454.57M	586.1M	350.24M	443.73M	404.91M
Equity Growth %	-	-15.09%	1.71%	0.29%	-0.4%	0.27%	-0.09%
Book Value per Share	0.18	-2.25	1.60	2.10	1.25	1.57	1.42
Total Shareholders' Equity	44.36M	-642.57M	452.3M	586.1M	350.24M	443.73M	404.91M
Common Stock	2.32M	2.32M	2.86M	2.86M	2.86M	2.86M	2.86M
Retained Earnings	-10.42M	-550.51M	-589.13M	-472.25M	-705.82M	-654.44M	-610.04M
Treasury Stock	0	0	-34M	-33.55M	-29.77M	-27.18M	-23.43M
Accumulated OCI	-109.96M	-94.39M	-93.84M	-83.57M	-106.65M	-92.68M	-208.25M
Minority Interest	1.13M	1.44M	2.27M	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	119.56M	149.04M	120.58M	281.55M	277.96M	-147.73M	224.16M
Operating CF Margin %	0.16%	0.19%	0.15%	0.3%	0.28%	-0.14%	0.2%
Operating CF Growth %	-	0.25%	-0.19%	1.33%	-0.01%	-1.53%	2.52%
Net Income	-5.88M	-20.43M	-37.49M	117.12M	-233.57M	51.38M	44.4M
Depreciation & Amortization	146.82M	146.72M	143.56M	150.9M	145.55M	160.34M	163.64M
Stock-Based Compensation	6.94M	6.88M	10.99M	13.87M	21.21M	32.24M	36.78M
Deferred Taxes	-45.32M	-18.99M	-23.36M	-3.72M	-73.96M	3.45M	9.43M
Other Non-Cash Items	12.96M	43.21M	38.68M	15.96M	9.49M	8.15M	12.55M
Working Capital Changes	4.04M	-8.35M	-11.79M	-12.59M	409.23M	-403.29M	-42.63M
Change in Receivables	-2.91M	11.76M	1.94M	-15.51M	-12.55M	-21.72M	2.22M
Change in Inventory	-7.04M	-282K	3.78M	-20.25M	14.44M	-9.97M	-4.75M
Change in Payables	15.13M	-8.97M	-6.02M	19.76M	1.11M	-5.33M	-6.64M
Cash from Investing+	96.64M	-57.26M	-158.69M	-159.83M	-181.9M	-214.91M	-179M
Capital Expenditures	-72.61M	-57.26M	-53.51M	-102.16M	-182.38M	-214.97M	-179.07M
CapEx % of Revenue	0.1%	0.07%	0.07%	0.11%	0.18%	0.2%	0.16%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	6.43M	0	0	-701K	32K	69K	74K
Cash from Financing+	-191.86M	-126.03M	73.43M	-117.29M	197.76M	265.96M	-50.56M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-175.84M	-691.17M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-1.38M	-18.38M	-21.2M	-15.85M	-1.85M	-27.45M	-34.38M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	46.95M	91.78M	67.08M	179.38M	95.58M	-362.71M	45.09M
FCF Margin %	0.06%	0.12%	0.08%	0.19%	0.1%	-0.35%	0.04%
FCF Growth %	-	0.95%	-0.27%	1.67%	-0.47%	-4.79%	1.12%
FCF per Share	0.19	0.32	0.24	0.64	0.34	-1.28	0.16
FCF Conversion (FCF/Net Income)	-20.37x	-7.15x	-3.12x	2.41x	-1.19x	-2.88x	5.05x
Interest Paid	138.85M	151M	211.28M	58.77M	75.85M	173.84M	179.92M
Taxes Paid	68.61M	44.61M	23.99M	52.01M	75.5M	50.21M	65.83M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-12.9%	-	-8.5%	22.46%	-49.89%	12.94%	10.46%
Return on Invested Capital (ROIC)	2.77%	6.36%	7.01%	8.43%	8.68%	9.3%	9.01%
Gross Margin	47.88%	50.81%	54.22%	55.68%	55.5%	55%	54.73%
Net Margin	-0.79%	-2.68%	-4.72%	12.55%	-23.27%	4.9%	4.03%
Debt / Equity	49.19x	-	4.20x	3.12x	5.80x	5.24x	5.81x
Interest Coverage	0.56x	1.16x	0.96x	3.46x	3.10x	1.94x	1.81x
FCF Conversion	-20.37x	-7.15x	-3.12x	2.41x	-1.19x	-2.88x	5.05x
Revenue Growth	-	4.31%	5.12%	13.85%	7.75%	4.54%	4.88%

Revenue by Segment

	2021	2022	2023	2024
Service	805.5M	864.83M	905.6M	941.82M
Service Growth	-	7.37%	4.71%	4.00%
Product	125.98M	138.86M	143.69M	158.62M
Product Growth	-	10.23%	3.48%	10.39%

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	527.91M	579.02M	590.97M	616.68M
UNITED STATES Growth	-	9.68%	2.06%	4.35%
CANADA	177.88M	188.74M	192.05M	208.89M
CANADA Growth	-	6.11%	1.75%	8.77%
Europe	161.81M	166.03M	187.54M	196.01M
Europe Growth	-	2.60%	12.96%	4.52%
Other Geographical Areas	63.89M	69.9M	78.73M	78.86M
Other Geographical Areas Growth	-	9.42%	12.63%	0.17%

Frequently Asked Questions

Valuation & Price

Sotera Health Company (SHC) has a price-to-earnings (P/E) ratio of 120.9x. This suggests investors expect higher future growth.

Growth & Financials

Sotera Health Company (SHC) reported $1.15B in revenue for fiscal year 2024. This represents a 54% increase from $746.1M in 2018.

Sotera Health Company (SHC) grew revenue by 4.9% over the past year. Growth has been modest.

Yes, Sotera Health Company (SHC) is profitable, generating $55.4M in net income for fiscal year 2024 (4.0% net margin).

Dividend & Returns

Sotera Health Company (SHC) has a return on equity (ROE) of 10.5%. This is reasonable for most industries.

Sotera Health Company (SHC) generated $85.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.